We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-12.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.27B
AUM Growth
-$685M
Cap. Flow
+$21.7M
Cap. Flow %
0.66%
Top 10 Hldgs %
61.39%
Holding
65
New
6
Increased
5
Reduced
5
Closed
10
Avg Time Held Equity + Options
1.8 years
Top 10 Avg Time Held Equity + Options
1.6 years
Top 20 Avg Time Held Equity + Options
1.9 years
Avg Time Held Equity only
1.8 years
Top 10 Avg Time Held Equity only
1.6 years
Top 20 Avg Time Held Equity only
1.9 years

Top Buys

Rank Stock Value
1
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$77M
2
JANX icon
Janux Therapeutics
JANX
+$69M
3
CRGX icon
CARGO Therapeutics
CRGX
+$27.9M
4
BCYC icon
Bicycle Therapeutics
BCYC
+$20.6M
5
ITOS icon
iTeos Therapeutics
ITOS
+$17.9M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$75M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$65.8M
3
ALEC icon
Alector
ALEC
+$24.4M
4
NKTX icon
Nkarta
NKTX
+$21.6M
5
OVID icon
Ovid Therapeutics
OVID
+$18.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Miscellaneous 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ADAP
26
DELISTED
Adaptimmune Therapeutics
ADAP
$26.7M 0.82%
27,404,070
– –
2024 Q1
1 quarter
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.32B
$24.2M 0.74%
3,418,068
– –
2020 Q2
16 quarters
CRGX icon
28
DELISTED
CARGO Therapeutics
CRGX
$24.1M 0.74%
+1,470,000
New +$27.9M
2024 Q2
0 quarters
CLDX icon
29
Celldex Therapeutics
CLDX
$2.27B
$24.1M 0.74%
650,000
– –
2024 Q1
1 quarter
PCVX icon
30
Vaxcyte
PCVX
$10.3B
$22.7M 0.69%
300,000
– –
2024 Q1
1 quarter
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.15B
$22.5M 0.69%
1,250,385
– –
2021 Q1
13 quarters
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$3.4B
$21.9M 0.67%
1,346,475
-4,645,004
-78% -$75M
2021 Q4
10 quarters
LENZ icon
33
LENZ Therapeutics
LENZ
$112M
$21.1M 0.65%
1,219,774
– –
2021 Q4
10 quarters
MDGL icon
34
Madrigal Pharmaceuticals
MDGL
$10.6B
$21M 0.64%
75,000
– –
2024 Q1
1 quarter
NMRA icon
35
Neumora Therapeutics
NMRA
$80.2M
$20.4M 0.62%
2,071,450
– –
2023 Q3
3 quarters
BCYC icon
36
Bicycle Therapeutics
BCYC
$252M
$18.4M 0.56%
+910,000
New +$20.6M
2024 Q2
0 quarters
AVIR icon
37
Atea Pharmaceuticals
AVIR
$363M
$18M 0.55%
5,441,896
-703,965
-11% -$2.62M
2021 Q4
10 quarters
PHVS icon
38
Pharvaris
PHVS
$2.08B
$16.9M 0.52%
900,000
– –
2023 Q4
2 quarters
DYN icon
39
Dyne Therapeutics
DYN
$2.86B
$15.1M 0.46%
427,039
– –
2024 Q1
1 quarter
TECX icon
40
Tectonic Therapeutic
TECX
$416M
$14M 0.43%
+849,143
New +$13.6M
2024 Q2
0 quarters
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$259M
$10.9M 0.33%
+508,393
New +$11.7M
2024 Q2
0 quarters
KROS icon
42
Keros Therapeutics
KROS
$220M
$8.57M 0.26%
187,500
– –
2024 Q1
1 quarter
KLRS icon
43
Kalaris Therapeutics
KLRS
$52.1M
$8.17M 0.25%
491,069
– –
2024 Q1
1 quarter
REPL icon
44
Replimune Group
REPL
$1.11B
$7.65M 0.23%
+850,341
New +$5.93M
2024 Q2
0 quarters
VERV icon
45
DELISTED
Verve Therapeutics
VERV
$6.1M 0.19%
1,250,000
– –
2023 Q4
2 quarters
GBIO icon
46
DELISTED
Generation Bio
GBIO
$5.77M 0.18%
204,687
– –
2023 Q1
5 quarters
PRME icon
47
Prime Medicine
PRME
$655M
$3.6M 0.11%
700,000
– –
2024 Q1
1 quarter
ATRA icon
48
Atara Biotherapeutics
ATRA
$96.9M
$3.46M 0.11%
406,679
-3
-0% -$45
2023 Q4
2 quarters
PRQR icon
49
ProQR Therapeutics
PRQR
$205M
$3.39M 0.1%
2,042,771
-841,586
-29% -$1.63M
2023 Q1
5 quarters
HOOK icon
50
DELISTED
HOOKIPA Pharma
HOOK
$3.38M 0.1%
571,732
+112,230
+24% +$890K
2022 Q1
9 quarters
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2024 Portfolio in Review

As of Q2 2024, EcoR1 Capital held 65 positions worth $3.27B, down 17% from $3.95B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

EcoR1 Capital's Q2 2024 filing shows 6 new, 5 increased, 5 reduced and 10 closed positions. Its largest new stake was Janux Therapeutics: 1,469,818 shares worth $61.6M. The largest sale was Acadia Pharmaceuticals, an estimated $75M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2024 buy was Janux Therapeutics: 1,469,818 shares worth $61.6M.
  • EcoR1 Capital added most to Morphic Holding, Inc. Common Stock in Q2 2024, an estimated $77M increase.
  • EcoR1 Capital's biggest Q2 2024 reduction was Acadia Pharmaceuticals, cutting an estimated $75M.
  • EcoR1 Capital fully exited Alector in Q2 2024, selling an estimated $24.4M.
  • EcoR1 Capital's ten largest holdings make up 61% of its $3.27B portfolio in Q2 2024.
  • EcoR1 Capital opened 6 new positions and closed 10 in Q2 2024.
  • EcoR1 Capital's portfolio value fell 17% quarter-over-quarter to $3.27B.

Based on EcoR1 Capital's 13F filing for Q2 2024, filed 14 Aug 2024.